Journal
NANOMEDICINE
Volume 14, Issue 12, Pages 1605-1621Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2018-0478
Keywords
cancer metastasis; drug delivery; formulation; lymphatic; nanomedicine; PEGylation; pharmacokinetics; poly(ethylene glycol); prodrugs
Funding
- NHMRC Career Development fellowship
Ask authors/readers for more resources
Lymphatic metastasis plays an important role in cancer progression and prognosis. However, conventional small-molecule chemotherapy drugs inefficiently access the lymphatic system, making the effective eradication of lymphatic metastases difficult without dose-limiting toxicity. Various formulation and nanomedicine-based approaches can be used to significantly enhance the trafficking of small-molecule, peptide and protein drugs toward the lymphatic system to enhance drug exposure at sites of lymphatic cancer growth. However, a number of obstacles exist in translating improved lymphatic exposure into improved chemotherapeutic outcomes. This review highlights the opportunities and challenges inherent in employing formulation and nanomedicinal approaches to improve chemotherapeutic drug activity within the lymphatic system and, importantly, at sites of lymphatic cancer metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available